Cytokinetics, Incorporated
CYTK
주식 순위
#2262
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
주가
$64.11
마지막 동기화: 2026-10-20
시가총액
$8.91B
변동 (1일)
2.34%
변동 (1년)
10.96%
국가
US
거래 Cytokinetics, Incorporated (CYTK)
카테고리
Healthcare
Cytokinetics, Incorporated (CYTK)의 매출
Jun 2026 기준 매출 TTM: $70.96M
Cytokinetics, Incorporated의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $70.96M입니다. 2023년에 회사는 $7.53M의 수익을 올렸으며 이는 2022년의 $94.59M 대비 감소입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Cytokinetics, Incorporated의 수익 기록 (2000 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $70.96M | 284.11% |
| 2024 | $18.47M | 145.34% |
| 2023 | $7.53M | -92.04% |
| 2022 | $94.59M | 34.30% |
| 2021 | $70.43M | 26.15% |
| 2020 | $55.83M | 107.79% |
| 2019 | $26.87M | -14.71% |
| 2018 | $31.50M | 135.64% |
| 2017 | $13.37M | -87.44% |
| 2016 | $106.41M | 271.30% |
| 2015 | $28.66M | -38.95% |
| 2014 | $46.94M | 53.16% |
| 2013 | $30.65M | 305.45% |
| 2012 | $7.56M | 88.98% |
| 2011 | $4.00M | 55.22% |
| 2010 | $2.58M | -96.84% |
| 2009 | $81.54M | 556.51% |
| 2008 | $12.42M | -8.82% |
| 2007 | $13.62M | 335.63% |
| 2006 | $3.13M | -64.91% |
| 2005 | $8.91M | -33.70% |
| 2004 | $13.44M | 27.09% |
| 2003 | $10.58M | -7.19% |
| 2002 | $11.40M | 34.61% |
| 2001 | $8.47M | 0.00% |
| 2000 | 0.00 | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 17,690.73% |
US
|
|
| $2.23B | 3,039.80% |
US
|
|
| $15.74B | 22,087.61% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 8,385.47% |
NL
|
